Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Q1 2023 Earnings Conference Call April 27, 2023 8:00 AM ET
Company Participants
Nareg Sagherian - Executive Director, Investor Relations
Jerry Durso - President and Chief Executive Officer
Dr. Michelle Berrey - President, Research & Development and Chief Medical Officer
Andrew Saik - Chief Financial Officer
Linda Richardson - Chief Commercial Officer
Conference Call Participants
Yasmeen Rahimi - Piper Sandler
Mayank Mamtani - B. Riley Securities
Ritu Baral - Cowen
Ryan Deschner - Raymond James
Joseph Stringer - Needham and Company
Brian Skorney - R.W. Baird
Thomas Smith - SVB Securities
Jon Wolleben - JMP Securities
Ellie Merle - UBS
Michael Yee - Jefferies
Brian Abrahams - RBC Capital Markets
Jay Olson - Oppenheimer
Ed Arce - H.C. Wainwright
Operator
Good day and thank you for standing by. Welcome to the First Quarter 2023 Intercept Pharmaceuticals Earnings Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and answer-session. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today Nareg Sagherian, Executive Director of Investor Relations. Please go ahead.
Nareg Sagherian
Good morning and thank you for joining us on today's call to review Intercept's first quarter 2023 financial results and key business updates. We are also pleased to share an overview of our commercial launch strategy for OCA in NASH.
Our first Quarter 2023 press release and accompanying slides are now on our website at intercept pharma.com. Before we begin our discussion, I'd like to note that we will be making forward-looking statements, including statements regarding our approved product and clinical development program, certain regulatory matters and our strategy, prospects, financial guidance and future commercial and financial performance.
Listeners are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this call, and we undertake no obligation to update such statements except as required by law. These forward-looking statements are based on estimates and assumptions that, although believed to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties.
Some, but not necessarily all of the risk factors that could cause our actual results to differ materially from our historical results or those anticipated or predicted by our forward-looking statements are discussed in this morning's press release and in our periodic public filings with the SEC.